UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1188-10
Program Prior Authorization/Notification
Medication Ocaliva® (obeticholic acid)
P&T Approval Date 5/2016, 6/2017, 6/2018, 6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 6/2024,
6/2025
Effective Date 9/1/2025
1. Background:
Ocaliva (obeticholic acid), a farnesoid X receptor (FXR) agonist, is indicated for the treatment
of primary biliary cholangitis (PBC), without cirrhosis or with compensated cirrhosis without
evidence of portal hypertension, in combination with ursodeoxycholic acid (UDCA) in adults
with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction in alkaline
phosphatase (ALP). An improvement in survival or disease-related symptoms has not been
established. Continued approval for this indication may be contingent upon verification and
description of clinical benefit in confirmatory trials.
2. Coverage Criteriaa:
A. Initial Authorization
1. Ocaliva will be approved based on all of the following criteria:
a. Diagnosis of primary biliary cholangitis
-AND-
b. One of the following:
(1) Patient does not have cirrhosis
-OR-
(2) Patient has compensated cirrhosis without evidence of portal hypertension
-AND-
c. One of the following:
(1) Both of the following:
(a) Used in combination with ursodeoxycholic acid (e.g., ursodiol)
(b) Patient has not achieved an adequate response to an appropriate dosage of
ursodeoxycholic acid (e.g., ursodiol) after at least 12 consecutive months of
therapy
© 2025 UnitedHealthcare Services Inc.
1
-OR-
(2) History of contraindication or intolerance to ursodeoxycholic acid (e.g., ursodiol)
Initial authorization will be issued for 12 months
B. Reauthorization
1. Ocaliva will be approved based on the following criterion:
a. Documentation of positive clinical response to Ocaliva therapy
Reauthorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place
• Medical necessity may be in place
• Step Therapy may be in place
4. References:
1. Ocaliva [package insert]. Morristown, NJ: Intercept Pharmaceuticals, Inc.; May 2022.
Program Prior Authorization/Notification – Ocaliva (obeticholic acid)
Change Control
Date Change
5/2016 New program.
6/2016 Changed clinical criteria based on FDA approved label.
6/2017 Annual review with no changes to clinical criteria. Updated Clinical Rules
to include that Step Therapy may be in place.
6/2018 Annual review with no changes to clinical criteria. Updated references.
6/2019 Annual review with no changes.
6/2020 Annual review. Added black box warning information.
6/2021 Annual review. No changes to clinical criteria.
6/2022 Annual review. Changed clinical criteria based on changes to prescribing
information. Revised order of listing of two criteria to better align with
prescribing information. Background and reference updated.
6/2023 Annual review with no changes to coverage criteria. Added state mandate
and updated reference.
6/2024 Annual review. Updated initial authorization to 12 months.
© 2025 UnitedHealthcare Services Inc.
2
6/2025 Annual review. Updated list of examples of ursodeoxycholic acid.
© 2025 UnitedHealthcare Services Inc.
3